LC
RCKT icon

Lindbrook Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Lindbrook Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$13.6K Buy
2,036
+1,385
+213% +$13.7K ﹤0.01% 1526
2024
Q4 		$8.18K Buy
651
+537
+471% +$8.08K ﹤0.01% 1756
2024
Q3 		$2.11K Sell
114
-103
-47% -$2.11K ﹤0.01% 2324
2024
Q2 		$4.67K Buy
217
+43
+25% +$988 ﹤0.01% 2029
2024
Q1 		$4.69K Buy
174
+5
+3% +$142 ﹤0.01% 1922
2023
Q4 		$5.07K Sell
169
-14
-8% -$309 ﹤0.01% 1881
2023
Q3 		$3.75K Buy
183
+95
+108% +$1.73K ﹤0.01% 1898
2023
Q2 		$1.75K Hold
88
– – ﹤0.01% 2202
2023
Q1 		$1.51K Hold
88
– – ﹤0.01% 2351
2022
Q4 		$1.72K Hold
88
– – ﹤0.01% 2296
2022
Q3 		$1K Hold
88
– – ﹤0.01% 2462
2022
Q2 		$1K Buy
+88
New +$1.05K ﹤0.01% 2342
2021
Q2 		– Sell
-236
Closed -$10K – 1993
2021
Q1 		$10K Sell
236
-1,364
-85% -$74.9K ﹤0.01% 1027
2020
Q4 		$88K Sell
1,600
-100
-6% -$3.65K 0.02% 265
2020
Q3 		$39K Buy
+1,700
New +$41.9K 0.01% 420
2020
Q2 		– Sell
-1,500
Closed -$21K – 1858
2020
Q1 		$21K Hold
1,500
– – 0.01% 527
2019
Q4 		$34K Sell
1,500
-1,500
-50% -$25.1K 0.01% 560
2019
Q3 		$35K Buy
3,000
+2,000
+200% +$24.8K 0.01% 530
2019
Q2 		$15K Buy
+1,000
New +$17.5K 0.01% 785
2019
Q1 		– Sell
-500
Closed -$7K – 1484
2018
Q4 		$7K Buy
+500
New +$8.3K ﹤0.01% 926

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's RCKT Position: Q1 2025 in Review

Lindbrook Capital increased its Rocket Pharmaceuticals (RCKT) stake by 213% in Q1 2025, buying an estimated $13.7K and bringing the position to 2,036 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Lindbrook Capital first reported a position in RCKT in Q4 2018 and has held it in 20 quarters since. The position peaked at $88K in Q4 2020. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Lindbrook Capital held 2,036 shares of Rocket Pharmaceuticals worth $13.6K as of Q1 2025.
  • Lindbrook Capital bought 1,385 Rocket Pharmaceuticals shares in Q1 2025, an estimated $13.7K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1526 holding.
  • Lindbrook Capital first reported a position in Rocket Pharmaceuticals in Q4 2018 and has held it in 20 quarters since.
  • Lindbrook Capital's Rocket Pharmaceuticals position peaked at $88K in Q4 2020.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.